CAR-Based Immunotherapy of Solid Tumours-A Survey of the Emerging Targets

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• CAR T-cell immunotherapy has transformed B-cell and plasma cell cancer treatment.
• Solid tumors present significant challenges for CAR T-cell therapy compared to hematological malignancies.
• Previous clinical trials targeting 30 antigens in solid tumors showed limited efficacy and notable toxicity.

Purpose of the Study:

• To review preclinical data for approximately 60 additional CAR target antigens for solid tumors.
• To identify promising candidates for future clinical evaluation in solid tumor immunotherapy.

Main Methods:

• Literature review of preclinical data for potential CAR target antigens.
• Analysis of existing clinical trial data for CAR T-cell therapy in solid tumors (from a partner review).

Main Results:

• Efficacy of CAR T-cell therapy in solid tumors lags behind hematological malignancies.
• Significant toxic events have been reported in clinical trials for solid tumors.
• Preclinical data support the advancement of ~60 new CAR target candidates for solid tumors.

Conclusions:

• CAR T-cell therapy for solid tumors requires further development and optimization.
• Identifying and validating novel CAR targets is crucial for improving treatment outcomes.
• Additional research into these 60 candidates may lead to more effective solid tumor immunotherapies.